Literature DB >> 28751768

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.

M Jawhar1, N Naumann1, M Knut2, J Score2, M Ghazzawi2, B Schneider3, K-A Kreuzer3, M Hallek3, H G Drexler4, J Chacko5, L Wallis5, A Fabarius1, G Metzgeroth1, W-K Hofmann1, A Chase2, W Tapper2, A Reiter1, N C P Cross2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28751768      PMCID： PMC5630086          DOI： 10.1038/leu.2017.240

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.

Authors:  G Metzgeroth; J Schwaab; D Gosenca; A Fabarius; C Haferlach; A Hochhaus; N C P Cross; W-K Hofmann; A Reiter
Journal:  Leukemia       Date:  2013-04-25       Impact factor: 11.528

2.  Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.

Authors:  Juliana Schwaab; Marcin Knut; Claudia Haferlach; Georgia Metzgeroth; Hans-Peter Horny; Andrew Chase; William Tapper; Joannah Score; Katherine Waghorn; Nicole Naumann; Mohamad Jawhar; Alice Fabarius; Wolf-Karsten Hofmann; Nicholas C P Cross; Andreas Reiter
Journal:  Ann Hematol       Date:  2014-09-27       Impact factor: 3.673

3.  Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing.

Authors:  A Pardanani; T Lasho; E Wassie; C Finke; D Zblewski; C A Hanson; R P Ketterling; N Gangat; A Tefferi
Journal:  Leukemia       Date:  2016-04-05       Impact factor: 11.528

Review 4.  The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes.

Authors:  M Maccaferri; V Pierini; D Di Giacomo; P Zucchini; F Forghieri; G Bonacorsi; A Paolini; C Quadrelli; F Giacobbi; F Fontana; G Cappelli; L Potenza; R Marasca; M Luppi; C Mecucci
Journal:  Leuk Lymphoma       Date:  2016-06-24

5.  High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

Authors:  Kathryn G Roberts; Zhaohui Gu; Debbie Payne-Turner; Kelly McCastlain; Richard C Harvey; I-Ming Chen; Deqing Pei; Ilaria Iacobucci; Marcus Valentine; Stanley B Pounds; Lei Shi; Yongjin Li; Jinghui Zhang; Cheng Cheng; Alessandro Rambaldi; Manuela Tosi; Orietta Spinelli; Jerald P Radich; Mark D Minden; Jacob M Rowe; Selina Luger; Mark R Litzow; Martin S Tallman; Peter H Wiernik; Ravi Bhatia; Ibrahim Aldoss; Jessica Kohlschmidt; Krzysztof Mrózek; Guido Marcucci; Clara D Bloomfield; Wendy Stock; Stephen Kornblau; Hagop M Kantarjian; Marina Konopleva; Elisabeth Paietta; Cheryl L Willman; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

6.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

Review 7.  Myeloid neoplasms with eosinophilia.

Authors:  Andreas Reiter; Jason Gotlib
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

8.  Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases.

Authors:  José L Vizmanos; Roberto Hernández; María J Vidal; María J Larráyoz; María D Odero; Julián Marín; María T Ardanaz; María J Calasanz; Nicholas C P Cross
Journal:  Hematol J       Date:  2004

Review 9.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

10.  Establishment of a novel human myeloid leukaemia cell line (FKH-1) with t(6;9)(p23;q34) and the expression of dek-can chimaeric transcript.

Authors:  H Hamaguchi; K Nagata; K Yamamoto; I Fujikawa; M Kobayashi; M Eguchi
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998
View more
  6 in total

1.  ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML.

Authors:  Barbara Spitzer; Filemon S Dela Cruz; Glorymar D Ibanez Sanchez; Yanming Zhang; Wenbin Xiao; Ryma Benayed; Alina Markova; M Irene Rodriguez-Sanchez; Nancy Bouvier; Mikhail Roshal; Andrew L Kung; Neerav Shukla
Journal:  Blood Adv       Date:  2021-04-13

Review 2.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

3.  Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.

Authors:  Aline Renneville; Jessica A Gasser; Daniel E Grinshpun; Pierre M Jean Beltran; Namrata D Udeshi; Mary E Matyskiela; Thomas Clayton; Marie McConkey; Kaushik Viswanathan; Alexander Tepper; Andrew A Guirguis; Rob S Sellar; Sophie Cotteret; Christophe Marzac; Véronique Saada; Stéphane De Botton; Jean-Jacques Kiladjian; Jean-Michel Cayuela; Mark Rolfe; Philip P Chamberlain; Steven A Carr; Benjamin L Ebert
Journal:  Blood Cancer Discov       Date:  2021-03-10

4.  Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18.

Authors:  Michael Maher; Jeannine Diesch; Marguerite-Marie Le Pannérer; Marta Cabezón; Mar Mallo; Sara Vergara; Aleix Méndez López; Alba Mesa Tudel; Francesc Solé; Marc Sorigue; Lurdes Zamora; Isabel Granada; Marcus Buschbeck
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

5.  Targeted Protein Degradation: An Important Tool for Drug Discovery for "Undruggable" Tumor Transcription Factors.

Authors:  Mengyuan Dai; Sridhar Radhakrishnan; Rui Li; Ruirong Tan; Kuo Yan; Gang Fan; Miao Liu
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.

Authors:  Claudia Chiriches; Dilawar Khan; Maria Wieske; Nathalie Guillen; Michal Rokicki; Carol Guy; Marieangela Wilson; Kate J Heesom; Oliver Gerhard Ottmann; Martin Ruthardt
Journal:  Ann Hematol       Date:  2022-08-08       Impact factor: 4.030
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.